Global Orphan Drugs Market: Snapshot

The increasing focus on the improvement of the healthcare infrastructure and medical sector are estimated to encourage the growth of the orphan drugs market over the next few years. As per the research study by TMR, the global market for orphan drugs is predicted to reach a value of US$318.5 bn by 2025. The market is expected to register 12.10% CAGR between 2017 and 2025.

View Report-

https://www.transparencymarketresearch.com/orphan-drugs-market.html

Rising Cases of Cancer to Propel Orphan Drugs Market in Coming Years

The rise in the number of cancer patients and the high growth of the oncology segment are the major factors that are projected to ensure the enhancement of the orphan drugs market in the coming few years. The discovery of different types of rare cancers and the development of early diagnostic techniques are further projected to encourage the growth of the market in the next few years. The rising focus of the players on research activities are expected to boost the growth of the orphan drugs market in the next few years. In addition to this, the rising cases of metabolic and cardiovascular are likely to boost the demand for orphan drugs in the next few years.

On the other hand, the high cost of development of drugs is one of the major factors that is estimated to inhibit the growth of the overall orphan drugs market in the coming years. Moreover, the lack of awareness among people regarding the availability of drugs and treatments are estimated to curtail its growth in the coming years. Nevertheless, the rising number of government initiatives and the increasing investments by the key players are projected to offer lucrative opportunities over the next few years.

Request A Sample-

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1254

High Research Activities to Support Growth across North America Orphan Drugs Market

The presence of a well-established healthcare infrastructure is anticipated to encourage the development of the orphan drugs market across North America in the coming few years. The favorable rules and regulations related to the approval of drugs for rare disorders and the rising initiatives by non-governmental and governmental agencies in order to raise awareness among people are expected to ensure the development of the market in the near future. In addition to this, the growing focus of the players on the research and development activities is predicted to support the growth of the market in the coming years.

The global market for orphan drugs is expected to have a competitive environment among the prominent players that are operating worldwide. The rise in the number of players that are projected to enter the market over the next few years is likely to add to the competitiveness. In the last few years, there has been a tremendous rise in the development of drugs and the rapid development of biopharmaceutical sector are estimated to support the growth of the market in the coming few years.

Request Brochure-

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1254

In addition to this, the increasing investments by the key players for the research activities is predicted to generate growth opportunities, thus accelerating the growth of the overall market in the next few years. The prominent players engaged in the orphan drugs market across the globe are Johnson & Johnson, Alexion Pharmaceuticals Inc., Amgen Inc., F. Hoffmann-La Roche Ltd., AstraZeneca plc., Bayer AG, GlaxoSmithKline plc., Shire plc., Eisai Co. Ltd., Novartis AG, Pfizer Inc., Bristol-Myers Squibb Company, Sanofi S.A., Novo Nordisk A/S, Eli Lilly and Company, Merck & Co. Inc., Biogen Inc., and Celgene Corporation.